Clinical trials: Stroke Risk
Post Stroke Epilepsy
Anti-epileptogenic Effects of Eslicarbazepine Acetate
This study aims to assess if eslicarbazepine acetate (ESL) treatment (started within 96 hours after stroke occurrence and continued for 30 days) changes the incidence of unprovoked seizures (USs) within the first 6 months after…
- Trial name
- NCT06597084
- Testing
- ESL 800 mg
- Where
- 22 sites in Austria, France and 7 more
- Volunteers
- 129 people
- Sponsor
- Bial - Portela C S.A.
Ischemic Stroke
Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
PRIMARY HYPOTHESIS: Compared with intensive medical therapy alone, intracranial angioplasty and stenting combined with intensive medical therapy will decrease the risk of the primary endpoint by 35% over a mean follow-up of two…
- Trial name
- SAMMPRIS (NCT00576693)
- Testing
- intracranial angioplasty and stenting, intensive medical management
- Where
- 50 sites in United States
- Volunteers
- 451 people
- Sponsor
- Medical University of South Carolina
Heart Diseases, Stroke
The HARMONY Study: A Intervention to Reduce Cardiometabolic Risk in African American Women
This study will test whether a culturally-tailored nutrition and exercise intervention designed for African-American women will lead to sustained improvements in exercise and healthy eating through improvements in self-management…
- Conditions
- Heart Diseases, Stroke, Pre-diabetes, Hypertension
- Trial name
- NCT04705779
- Testing
- HARMONY, Nutrition and Exercise Education (NEEW)
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- University of North Carolina, Chapel Hill
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Prevention of Stroke or Systemic Embolism, Atrial Fibrillation
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
Researchers are looking for a better way to treat people with atrial fibrillation (AF) and prevent stroke or systemic embolism (blood clots travelling through the blood stream to plug another vessel).
- Trial name
- OCEANIC-AF (NCT05643573)
- Testing
- Asundexian (BAY2433334), Apixaban
- Where
- 1,069 sites in United States, Argentina and 36 more
- Volunteers
- 14,830 people
- Sponsor
- Bayer
Stroke, Transient Ischemic Attack
Reducing Stroke Risk in African-American Men
The project is a 6-month prospective Randomized Controlled Trial evaluating the effects of TargEted MAnageMent Intervention (TEAM, N=80) vs.
- Trial name
- TEAM2 (NCT04402125)
- Testing
- TargEted MAnageMent Intervention (TEAM)
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- Case Western Reserve University
Atherosclerosis
Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging
The goal of this study is to assess a slimy substance that settles/deposits along blood vessel wall. This slimy substance is called plaque. Plaque could be made up of fat, calcium or both. Plaque deposition narrows the vessels.
- Trial name
- NCT02114697
- Testing
- Statin therapy, Lifestyle modification
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke
Registry on WATCHMAN Outcomes in Real-Life Utilization
The WATCHMAN LAA Closure Technology is designed to prevent embolization of thrombi that may form in the LAA, thereby preventing the occurrence of ischemic stroke and systemic thromboembolism.
- Trial name
- EWOLUTION (NCT01972282)
- Testing
- WATCHMAN Left Atrial Appendage Closure
- Where
- 47 sites in Belgium, France and 11 more
- Volunteers
- 1,025 people
- Sponsor
- Boston Scientific Corporation
Transient Ischemic Attack, Stroke
Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure
The goal of this study is to develop a novel study design to safely and ethically conduct a long-term randomized controlled trial among patients at high risk for both sleep apnea and cardiovascular events that will examine…
- Trial name
- SleepTight (NCT01446913)
- Testing
- Standard CPAP Intervention, Enhanced CPAP Intervention
- Where
- 2 sites in United States
- Volunteers
- 255 people
- Sponsor
- Yale University
Cardiovascular Disease, Stroke
A Personalized Dashboard to Educate Veterans at Risk of Stroke
Personalized risk communication methods have been used to educate patients that are at a high risk of developing cardiovascular disease.
- Trial name
- NCT01133171
- Testing
- Nurse Alone, Dashboard Plus Nurse
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- VA Office of Research and Development
Cerebral Palsy, Developmental Delay
SmarToyGym: Smart Detection of Atypical Toy-oriented Actions in At-risk Infants
The study aims to develop a SmarToyGym where sensitized, wireless toys are strategically hung and placed within reach of infants to elicit toy-oriented body and arm/hand movements.
- Conditions
- Cerebral Palsy, Developmental Delay, Stroke, Fine Motor Delay
- Trial name
- NCT02813889
- Testing
- SmarToyGym
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Nonvalvular Atrial Fibrillation
Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation
The main purpose of this study is to provide dose-guiding information by assessing the safety and tolerability of 4 different dosing regimens of an extended-release (ER) formulation of AZD0837 compared with well-controlled…
- Trial name
- NCT00684307
- Testing
- AZD0837, Vitamin-K antagonist at INR 2-3
- Volunteers
- 1,084 people
- Sponsor
- AstraZeneca
Atrial Fibrillation, Cardioversion
Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Patients with atrial fibrillation undergoing cardioversion will be randomized to undergo transesophageal echocardiography or they will receive warfarin for 3 weeks with an international normalized ratio (INR) value between…
- Conditions
- Atrial Fibrillation, Cardioversion, Cerebrovascular Stroke
- Trial name
- AFTER-CV (NCT01924065)
- Testing
- Cardioversion, Oral Anticoagulant
- Where
- Turkey (Türkiye)
- Volunteers
- 112 people
- Sponsor
- Suleyman Demirel University
Cerebrovascular Diseases, Stroke
Computer-Aided Prevention System
Stroke is one of the most frequent and life-threatening diseases in Europe. About four stroke events occur per day in Luxembourg alone, and about 30% of these patients are affected by recurrent stroke within the following five…
- Conditions
- Cerebrovascular Diseases, Stroke, Cardiovascular Diseases, CVD Risk Factors
- Trial name
- CAPSYS (NCT02444715)
- Testing
- Standard care, CAPSYS
- Volunteers
- 94 people
- Sponsor
- Lübomira Spassova
The Focus of the Study is to Reduce the Risk of Stroke and Life-threatening Bleeding Events in Patients With Non-valvular Atrial Fibrillation
WATCHMAN FLX™ CT Study
WATCHMAN FLX™ CT is a prospective, single-arm, single-center, post-market investigation to assess device tissue coverage in subjects with non-valvular atrial fibrillation (AF) who receive the WATCHMAN FLX device to reduce the…
- Trial name
- NCT05324371
- Testing
- Watchman FLX Device
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Boston Scientific Corporation
Ventricular Tachycardia, Premature Ventricular Contraction
DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
The purpose of this study is to learn if taking a drug called direct oral anticoagulant after an ablation procedure keeps blood clots from forming and lowers the chance of having a stroke in patients with ventricular tachycardia…
- Conditions
- Ventricular Tachycardia, Premature Ventricular Contraction, Stroke
- Trial name
- STROKE-VT (NCT02666742)
- Testing
- DOAC, Aspirin
- Where
- 5 sites in United States, India
- Volunteers
- 246 people
- Sponsor
- Kansas City Heart Rhythm Institute
Cardiovascular Disease, Psychological Stress
Mindful Hearts Study: Mindfulness to Reduce Stress
The purpose of this study is to determine how a stress reduction program, called Mindfulness Based Stress Reduction (MBSR), compared to a health education program, improves well being and reduces the risk of heart disease in…
- Conditions
- Cardiovascular Disease, Psychological Stress, Stroke, Coronary Artery Disease
- Trial name
- NCT01784796
- Testing
- Mindfulness Based Stress Reduction, Health Education Program
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy
Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Renin-angiotensin-aldosterone system (RAAS) polymorphisms influence 24h arterial pressure fluctuation. Resistant systemic arterial hypertension (RSAH) has an increased risk of end organ damage and unfavourable prognosis, whereas…
- Conditions
- Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy, Myocardial Infarction, Stroke
- Trial name
- GENHART (NCT01173029)
- Testing
- Anti-hypertensive drug treatment
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- Universidade Gama Filho
Diabetes Mellitus, Hypertension
Impact of INsulin Sensitivity on Cardiovascular Risk Markers During 10-20 Years of FOllow up
The purpose of this study is to identify risk factors for insulin resistance and to investigate the influence of insulin sensitivity on development of cardiovascular risk markers like blood pressure, heart rate, body build…
- Conditions
- Diabetes Mellitus, Hypertension, Ischemic Heart Disease, Stroke
- Trial name
- INFO (NCT01412554)
- Where
- Norway
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-2 (NCT01975389)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,595 sites in United States, Argentina and 33 more
- Volunteers
- 10,564 people
- Sponsor
- Pfizer